Should We Include Connection Domain Mutations of HIV-1 Reverse Transcriptase in HIV Resistance Testing?
2007

HIV Mutation N348I and Drug Resistance

Sample size: 1377 publication Evidence: moderate

Author Information

Author(s): Matthias Götte

Primary Institution: McGill University

Hypothesis

Should connection domain mutations of HIV-1 reverse transcriptase be included in HIV resistance testing?

Conclusion

The N348I mutation in HIV-1 reverse transcriptase is associated with increased resistance to zidovudine and nevirapine.

Supporting Evidence

  • N348I is the 9th most prevalent RT-associated mutation among treatment-experienced patients.
  • N348I confers a 2-fold increase in AZT resistance compared to wild-type virus.
  • N348I is associated with an 8-fold increase in resistance to nevirapine.

Takeaway

Scientists found a common mutation in HIV that makes it harder to treat with certain drugs. This mutation shows up often in people who have been treated before.

Methodology

The study analyzed HIV sequences from a cohort in Canada, comparing treatment-experienced and treatment-naïve individuals.

Limitations

The clinical relevance of connection and RNase H mutations remains unclear.

Participant Demographics

Included treatment-experienced patients (n = 1,009) and treatment-naïve individuals (n = 368).

Digital Object Identifier (DOI)

10.1371/journal.pmed.0040346

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication